324 related articles for article (PubMed ID: 12414349)
1. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.
Tàssies D; Freire C; Pijoan J; Maragall S; Monteagudo J; Ordinas A; Reverter JC
Haematologica; 2002 Nov; 87(11):1185-91. PubMed ID: 12414349
[TBL] [Abstract][Full Text] [Related]
2. [Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol].
Márk L; Márki-Zay J; Fodor L; Kondacs A; Paragh G; Katona A
Orv Hetil; 2005 Apr; 146(16):739-43. PubMed ID: 15889670
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450 2C9 polymorphism and acenocoumarol therapy.
Mark L; Marki-Zay J; Fodor L; Hajdara I; Paragh G; Katona A
Kardiol Pol; 2006 Apr; 64(4):397-402; discussion 403-4. PubMed ID: 16699986
[TBL] [Abstract][Full Text] [Related]
4. Acenocoumarol stabilization is delayed in CYP2C93 carriers.
Schalekamp T; van Geest-Daalderop JH; de Vries-Goldschmeding H; Conemans J; Bernsen Mj Mj; de Boer A
Clin Pharmacol Ther; 2004 May; 75(5):394-402. PubMed ID: 15116052
[TBL] [Abstract][Full Text] [Related]
5. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.
Schalekamp T; Oosterhof M; van Meegen E; van Der Meer FJ; Conemans J; Hermans M; Meijerman I; de Boer A
Clin Pharmacol Ther; 2004 Nov; 76(5):409-17. PubMed ID: 15536456
[TBL] [Abstract][Full Text] [Related]
6. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.
Peyvandi F; Spreafico M; Siboni SM; Moia M; Mannucci PM
Clin Pharmacol Ther; 2004 Mar; 75(3):198-203. PubMed ID: 15001971
[TBL] [Abstract][Full Text] [Related]
7. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants.
Visser LE; van Schaik RH; van Vliet M; Trienekens PH; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
Clin Pharmacol Ther; 2005 Jun; 77(6):479-85. PubMed ID: 15961979
[TBL] [Abstract][Full Text] [Related]
8. Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype.
Thijssen HH; Ritzen B
Clin Pharmacol Ther; 2003 Jul; 74(1):61-8. PubMed ID: 12844136
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of acenocoumarol pharmacodynamics.
Morin S; Bodin L; Loriot MA; Thijssen HH; Robert A; Strabach S; Verstuyft C; Tregouet DA; Dubert L; Laurent-Puig P; Funck-Brentano C; Jaillon P; Beaune PH; Becquemont L
Clin Pharmacol Ther; 2004 May; 75(5):403-14. PubMed ID: 15116053
[TBL] [Abstract][Full Text] [Related]
10. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.
Visser LE; van Schaik RH; van Vliet M; Trienekens PH; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
Thromb Haemost; 2004 Jul; 92(1):61-6. PubMed ID: 15213846
[TBL] [Abstract][Full Text] [Related]
11. Interindividual variability in sensitivity to warfarin--Nature or nurture?
Loebstein R; Yonath H; Peleg D; Almog S; Rotenberg M; Lubetsky A; Roitelman J; Harats D; Halkin H; Ezra D
Clin Pharmacol Ther; 2001 Aug; 70(2):159-64. PubMed ID: 11503010
[TBL] [Abstract][Full Text] [Related]
12. Creating a genotype-based dosing algorithm for acenocoumarol steady dose.
Cerezo-Manchado JJ; Rosafalco M; Antón AI; Pérez-Andreu V; Garcia-Barberá N; Martinez AB; Corral J; Vicente V; González-Conejero R; Roldán V
Thromb Haemost; 2013 Jan; 109(1):146-53. PubMed ID: 23196355
[TBL] [Abstract][Full Text] [Related]
13. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.
Pilotto A; Seripa D; Franceschi M; Scarcelli C; Colaizzo D; Grandone E; Niro V; Andriulli A; Leandro G; Di Mario F; Dallapiccola B
Gastroenterology; 2007 Aug; 133(2):465-71. PubMed ID: 17681167
[TBL] [Abstract][Full Text] [Related]
14. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin.
Kamali F; Khan TI; King BP; Frearson R; Kesteven P; Wood P; Daly AK; Wynne H
Clin Pharmacol Ther; 2004 Mar; 75(3):204-12. PubMed ID: 15001972
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
Beinema M; Brouwers JR; Schalekamp T; Wilffert B
Thromb Haemost; 2008 Dec; 100(6):1052-7. PubMed ID: 19132230
[TBL] [Abstract][Full Text] [Related]
16. [Warfarin in the treatment of antiphospholipid syndrome].
Reshetniak TM; Kondrat'eva LV; Patrusheva NL; Patrushev LI
Ter Arkh; 2007; 79(5):47-54. PubMed ID: 17672075
[TBL] [Abstract][Full Text] [Related]
17. Effect of CYP2C9 and VKORC1 genetic polymorphisms on mean daily maintenance dose of acenocoumarol in South Indian patients.
Krishna Kumar D; Madhan S; Balachander J; Sai Chandran BV; Thamijarassy B; Adithan C
Thromb Res; 2013 Apr; 131(4):363-7. PubMed ID: 23473641
[TBL] [Abstract][Full Text] [Related]
18. Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users.
Verhoef TI; Redekop WK; Buikema MM; Schalekamp T; Van Der Meer FJ; Le Cessie S; Wessels JA; Van Schie RM; De Boer A; Teichert M; Visser LE; Maitland-Van Der Zee AH;
J Thromb Haemost; 2012 Apr; 10(4):606-14. PubMed ID: 22252093
[TBL] [Abstract][Full Text] [Related]
19. CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences.
Takahashi H; Wilkinson GR; Padrini R; Echizen H
Clin Pharmacol Ther; 2004 May; 75(5):376-80. PubMed ID: 15116049
[No Abstract] [Full Text] [Related]
20. Acenocoumarol and phenytoin toxicity in the presence of CYP2C9 mutation.
Jose L; Binila C; Chandy SJ; Mathews JE; Mathews KP
J Assoc Physicians India; 2008 Apr; 56():250-2. PubMed ID: 18702389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
